And based on data from the DAPA-CKD study and the EMPA-KIDNEY study, a lot of these individuals with modest reductions in GFR should receive SGLT-2 inhibitors. But recently data has come to ...

Its developers are also working on adding kidney claims via the EMPA-KIDNEY study, which only started last year however, and they are also going after a potentially first-in-class chronic heart ...

Results from EMPA-KIDNEY are due in 2022 ... on the strength of the DAPA-CKD study. Sales of J&J’s Invokana franchise rose quickly after its 2013 launch to almost $1.4 billion in 2016 before ...